These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 21922643

  • 1. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
    Schmid I, Häberle B, Albert MH, Corbacioglu S, Fröhlich B, Graf N, Kammer B, Kontny U, Leuschner I, Scheel-Walter HG, Scheurlen W, Werner S, Wiesel T, von Schweinitz D.
    Pediatr Blood Cancer; 2012 Apr; 58(4):539-44. PubMed ID: 21922643
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib in hepatocellular carcinoma - a post marketing evaluation.
    Trojniak MP, Palozzo AC, Mazurek M, Jirillo A.
    Immunopharmacol Immunotoxicol; 2012 Jun; 34(3):419-22. PubMed ID: 21981250
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK.
    Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.
    J Clin Oncol; 2006 Sep 10; 24(26):4293-300. PubMed ID: 16908937
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S, McTigue M, Finn RS, Busuttil RW.
    Exp Clin Transplant; 2010 Dec 10; 8(4):307-13. PubMed ID: 21143097
    [Abstract] [Full Text] [Related]

  • 6. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B, Yu J, Wang L, Li C, Zhou T, Zhai L, Xing L.
    Am J Clin Oncol; 2003 Aug 10; 26(4):e92-9. PubMed ID: 12902905
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
    Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL.
    J Hepatol; 2010 Jul 10; 53(1):126-31. PubMed ID: 20416968
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.
    Duan F, Wang MQ, Liu FY, Wang ZJ, Song P, Wang Y.
    Asia Pac J Clin Oncol; 2012 Jun 10; 8(2):156-63. PubMed ID: 22524574
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B.
    Liver Transpl; 2012 Jan 10; 18(1):45-52. PubMed ID: 21932373
    [Abstract] [Full Text] [Related]

  • 10. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.
    Richly H, Schultheis B, Adamietz IA, Kupsch P, Grubert M, Hilger RA, Ludwig M, Brendel E, Christensen O, Strumberg D.
    Eur J Cancer; 2009 Mar 10; 45(4):579-87. PubMed ID: 19101137
    [Abstract] [Full Text] [Related]

  • 11. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
    Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K.
    Eur J Cancer; 2011 Sep 10; 47(14):2117-27. PubMed ID: 21664811
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
    Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, Schuchmann M, Otto G, Galle PR, Wörns MA.
    Dig Liver Dis; 2012 May 10; 44(5):432-7. PubMed ID: 22265328
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
    Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, Woo SM, Nam BH.
    J Hepatol; 2012 Jun 10; 56(6):1336-42. PubMed ID: 22314421
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
    J Clin Gastroenterol; 2009 Jun 10; 43(5):489-95. PubMed ID: 19247201
    [Abstract] [Full Text] [Related]

  • 15. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
    Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH, Chen BB, Wei SY, Cheng AL, Shih TT.
    J Hepatol; 2011 Oct 10; 55(4):858-65. PubMed ID: 21338641
    [Abstract] [Full Text] [Related]

  • 16. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
    Kim HY, Park JW, Nam BH, Kim HK, Choi JI, Kim TH, Kim HB, Kim CM.
    J Gastroenterol Hepatol; 2011 Nov 10; 26(11):1612-8. PubMed ID: 21517968
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
    Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K.
    Cancer Chemother Pharmacol; 2004 Nov 10; 54(5):385-90. PubMed ID: 15248028
    [Abstract] [Full Text] [Related]

  • 18. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
    Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Aucejo F.
    Oncology; 2010 Nov 10; 79(1-2):62-6. PubMed ID: 21071991
    [Abstract] [Full Text] [Related]

  • 19. Adult type vs. Childhood hepatocellular carcinoma--are they the same or different lesions? Biology, natural history, prognosis, and treatment.
    Czauderna P.
    Med Pediatr Oncol; 2002 Nov 10; 39(5):519-23. PubMed ID: 12228910
    [Abstract] [Full Text] [Related]

  • 20. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Staufer K, Fischer L, Seegers B, Vettorazzi E, Nashan B, Sterneck M.
    Transpl Int; 2012 Nov 10; 25(11):1158-64. PubMed ID: 22882364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.